Cargando…
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/ https://www.ncbi.nlm.nih.gov/pubmed/26719190 http://dx.doi.org/10.1007/s40264-015-0383-8 |
_version_ | 1782413044393967616 |
---|---|
author | Klein, Kevin Scholl, Joep H. G. Vermeer, Niels S. Broekmans, André W. Van Puijenbroek, Eugène P. De Bruin, Marie L. Stolk, Pieter |
author_facet | Klein, Kevin Scholl, Joep H. G. Vermeer, Niels S. Broekmans, André W. Van Puijenbroek, Eugène P. De Bruin, Marie L. Stolk, Pieter |
author_sort | Klein, Kevin |
collection | PubMed |
description | INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly reported. We evaluated information-recording systems and practices in the Dutch hospital setting to identify determinants for brand name and batch number recording as well as success factors and bottlenecks for traceability. METHODS: We surveyed Dutch hospital pharmacists with an online questionnaire on systems and practices in hospitals for recording brand names and batch numbers. Additionally, we performed an analysis of the traceability of recombinant biologics in spontaneous ADR reports (received between 2009 and 2014) from the Netherlands Pharmacovigilance Centre Lareb. RESULTS: The survey showed that brand names are not routinely recorded in the clinical practice of Dutch hospitals, whereas batch numbers are poorly recorded. Seventy-six percent of the 1523 ADR reports for recombinant biologics had a traceable brand name whereas 5 % of these reports contained a batch number. The results suggest a possible relationship between the availability of brand and batch number information in clinical practice and the inclusion of this information in ADR reports for biologics. CONCLUSION: The limited traceability of brand names and batch numbers in ADR reports may be primarily caused by the shortcomings in the recording of information in clinical practice. We recommend efforts to improve information-recording systems as a first step to improve the traceability of biologics in ADR reporting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-015-0383-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4735237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-47352372016-02-09 Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports Klein, Kevin Scholl, Joep H. G. Vermeer, Niels S. Broekmans, André W. Van Puijenbroek, Eugène P. De Bruin, Marie L. Stolk, Pieter Drug Saf Original Research Article INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly reported. We evaluated information-recording systems and practices in the Dutch hospital setting to identify determinants for brand name and batch number recording as well as success factors and bottlenecks for traceability. METHODS: We surveyed Dutch hospital pharmacists with an online questionnaire on systems and practices in hospitals for recording brand names and batch numbers. Additionally, we performed an analysis of the traceability of recombinant biologics in spontaneous ADR reports (received between 2009 and 2014) from the Netherlands Pharmacovigilance Centre Lareb. RESULTS: The survey showed that brand names are not routinely recorded in the clinical practice of Dutch hospitals, whereas batch numbers are poorly recorded. Seventy-six percent of the 1523 ADR reports for recombinant biologics had a traceable brand name whereas 5 % of these reports contained a batch number. The results suggest a possible relationship between the availability of brand and batch number information in clinical practice and the inclusion of this information in ADR reports for biologics. CONCLUSION: The limited traceability of brand names and batch numbers in ADR reports may be primarily caused by the shortcomings in the recording of information in clinical practice. We recommend efforts to improve information-recording systems as a first step to improve the traceability of biologics in ADR reporting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-015-0383-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-12-30 2016 /pmc/articles/PMC4735237/ /pubmed/26719190 http://dx.doi.org/10.1007/s40264-015-0383-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Klein, Kevin Scholl, Joep H. G. Vermeer, Niels S. Broekmans, André W. Van Puijenbroek, Eugène P. De Bruin, Marie L. Stolk, Pieter Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title_full | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title_fullStr | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title_full_unstemmed | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title_short | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports |
title_sort | traceability of biologics in the netherlands: an analysis of information-recording systems in clinical practice and spontaneous adr reports |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/ https://www.ncbi.nlm.nih.gov/pubmed/26719190 http://dx.doi.org/10.1007/s40264-015-0383-8 |
work_keys_str_mv | AT kleinkevin traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT scholljoephg traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT vermeernielss traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT broekmansandrew traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT vanpuijenbroekeugenep traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT debruinmariel traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports AT stolkpieter traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports |